BAC's CaptureSelect customised affinity ligands have been selected by Sanofi Pasteur as they potentially offer high stability and specificity for process-scale purification of some vaccine products
BAC has entered into an agreement with Sanofi Pasteur, the vaccines business of Sanofi-Aventis.
Sanofi Pasteur is one of the world's largest companies dedicated to developing human vaccines.
Manufactured using a high-yielding proprietary yeast-based expression system, which is completely animal-free, CaptureSelect ligands exploit the nature of Camelid single chain antibody fragments and offer enhanced stability and broad antigen-specific binding compared to traditional affinity media.
BAC says it has built a strong reputation for rapid discovery and development of customised ligands for chromatographic separation of a wide range of biological materials including monoclonal antibodies, antibody fragments, recombinant proteins and micro organisms for biopharmaceutical manufacture.
"This is a significant collaboration for BAC and we are proud to have been selected by Sanofi Pasteur for this exciting project," said Laurens Sierkstra, CEO of BAC.
"This latest agreement further endorses the suitability of our CaptureSelect technology for commercial-scale bioprocessing".
BAC - the bio affinity company - offers a wide range of products and services for affinity purification of biological materials from complex media.
The company's proprietary CaptureSelect affinity ligands, based on Camelid single chain antibody fragments, have been proven to be suitable in a wide range of biological applications including life science research, biomanufacturing and healthcare.
CaptureSelect ligand technology is based on selection of single chain antibody fragments with desirable chromatographic characteristics including robustness, high specificity and flexibility.
Suitable ligands are cloned and expressed in high-titers through an animal-free Saccharomyces cerevisiae-based process.
BAC was established in 1995 as a Unilever subsidiary.
Currently the company employs 28 people with an R+D laboratory facility in Vlaardingen and a state-of-the-art ISO 9001 certified manufacturing plant in Naarden, Netherlands.
